CCDC112

Across TCGA pan-cancer cohorts, CCDC112 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC112 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher CCDC112 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC112 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, KIRC, and LUSC are the cancer types where CCDC112 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
KIRC	OS	Median	All	0.266	0.805	.017	12	view →
LUSC	OS	Median	All	0.238	0.776	.009	12	view →
UCEC	DFS	Median	All	0.957	0.613	.021	10	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC112–KICH (DFS)

Open the KICH breakdown →